45 results about "Dosing Frequency" patented technology

The present invention relates to an intelligent control method for coal slurry water concentration and dosing, which belongs to the field of intelligent control and includes the following steps: (a) collecting various parameters of the sedimentation process of the concentration tank; (b) preprocessing and feature engineering the collected data; (c) analyzing the correlation between the process parameters of the concentration tank and the sedimentation index, and calculating the maximum information coefficient between the variables through the MINE algorithm; (d) constructing a multi-algorithm prediction meta-model, and obtaining the optimal model weight combination through model fusion; (e) according to the real-time process parameters of the concentration tank and the height of the clear water layer and the overflow turbidity at the current moment, on the basis of the prediction meta-model, establishing an optimization model based on a genetic algorithm, and automatically adjusting the dosing frequency of the concentration tank under the premise of meeting the process parameter control index. The advantages of the present invention are: comprehensively considering the control conditions of the history and current period of the concentration tank, according to the model trained by historical data, the automatic control of the dosing system of the concentration tank is realized, and the dosing control operation can be timely and accurate.

The invention discloses a PLC-based conventional island dosing system and a control method. The PLC-based conventional island dosing system comprises an upper computer, sampling equipment and dosing equipment, wherein the sampling equipment and the dosing equipment are connected with a PLC; a rotating device in the dosing device is connected with the PLC through a DI card key; the ammonia water assembly is connected with a dosing pump module in the rotating equipment; the hydrazine assembly is connected with the dosing pump module, and the dosing pump module is further connected with the secondary loop system; a chemical instrument, an ammonia water assembly and a hydrazine assembly in the sampling equipment and each frequency converter in the dosing pump module are connected with the PLC through AI card keys; the PLC is also connected with the rotating equipment through a DO card key; the PLC is further connected with each frequency converter in the dosing pump module through an AO card key, the PLC monitors the water quality of a secondary loop system based on a chemical instrument in the sampling equipment so as to control the dosing frequency of any dosing pump in the dosing pump module, and then the full-automatic dosing function is achieved.

The present invention belongs to the field of biopharmaceuticals, and particularly relates to a multi-domain active protein for treating metabolic diseases. The multi-domain active protein has a structural formula as shown in Formula I: A-L a -F-L b -B. Compared with the prior art, the multi-domain active protein of the present invention has a long half-life and supports a once-weekly dosing frequency; the GLP-1R agonist activity of the multi-domain active protein is increased by more than 200 times at most; the multi-domain active protein has good stability in vivo and in vitro and low immunogenicity; since no unnatural amino acids need to be introduced and no chemical synthesis and cross-linking steps are involved, it can be prepared by a recombinant method, greatly simplifying the preparation process.

To provide an ophthalmic pharmaceutical composition comprising chlorpheniramine maleate as an active ingredient, the pharmaceutical composition being capable of sustaining therapeutic efficacy with reduced dosing frequency compared to eye drops.SOLUTION: The present invention provides a pharmaceutical composition comprising chlorpheniramine maleate as an active ingredient, the pharmaceutical composition being for use in administration to eyelid skin.SELECTED DRAWING: None

The invention discloses an application and a preparation of a miR-125b-5p inhibitor or antagonist for treating and / or preventing myopia. According to the application, a miR-125b-5p inhibitor or antagonist, particularly miR-125b-5p antiagomir with a nucleotide sequence as shown in SEQ ID NO: 8, is used for inhibiting the expression of miR-125b-5p in sclera and increasing the expression of a target gene tp53, so that the transdifferentiation of sclera fibroblasts can be remarkably reduced, sclera remodeling can be reduced, and the diopter reduction and ocular axis extension of guinea pig deprivation myopia can be retarded; the composition can be used for preventing myopia and controlling myopia progress, has the advantages of low administration frequency and high safety, and provides a safer, more effective and more convenient prevention and control means for myopia patients, especially teenagers.

The utility model relates to the technical field of dosing devices, and discloses a polyaluminum chloride quantitative dosing device which comprises a storage box, and a quantitative mechanism is arranged at the bottom of the storage box; the quantifying mechanism comprises two supports, a protection box and an electric push rod, guide rails are fixedly connected to the inner side walls of the two supports, and an L-shaped supporting frame is fixedly connected to the bottom of the rear support. Through the arrangement of the quantifying mechanism, the problem that the continuity and the stability of the water treatment process are influenced due to inconsistent dosing intervals caused by the fact that the dosing amount of each time cannot be accurate and the dosing frequency cannot be stably controlled can be solved; and the medicine can flow into a leakage cylinder through a conveying pipe at the bottom of a storage box, so that the continuity and stability of the device are effectively improved, and the dosage and frequency of the medicine can be accurately controlled.

The present invention relates to therapeutic compositions and methods for the treatment of attention deficit disorder (ADD), or attention deficit hyperactivity disorder (ADHD). The present invention more particularly relates to a modified-release pharmaceutical formulation designed to improve the delivery and efficacy of central nervous system (CNS) stimulants. The composition consists of a drug-containing core with a CNS stimulant and pharmaceutically acceptable excipients. This core is coated with a sustained-release (SR) layer comprising one or more polymers selected from water-insoluble and water-insoluble pH-dependent polymers, and one or more pharmaceutically acceptable excipients which regulates the gradual release of the drug. Surrounding the SR layer is a delayed-release (DR) outer layer that controls the onset of drug release. This approach aims to enhance symptom control, reduce dosing frequency, and improve patient compliance in the treatment of ADD and ADHD.

This invention describes a novel, stable, fixed-dose, aqueous suspension of Amoxicillin Clavulanate for nasal administration to treat post-surgical nasal infections. The formulation leverages a unique combination of excipients, including mucoadhesive agents like chitosan, to enhance drug delivery and efficacy. Key features include targeted delivery to the infection site, sustained release for reduced dosing frequency, and the ability to disrupt bacterial biofilms. This innovative approach addresses the limitations of current treatment options by providing effective local drug delivery, minimizing systemic side effects, and improving patient compliance.

The present invention provides an antibody or antigen-binding portion thereof that can bind to properdin (factor P). The antibody of the current invention leads to selective inhibition of alternative complement pathway while allowing the classical and lectin pathways to continue. Further, the antibody of the present invention may have modified or reduced binding to FcγRs to minimize its ADCC activity. The present invention provide an antibody that comprises an amino acid sequence to minimise its CDC activity. The antibody according to the present invention has higher FcRn binding affinity and therefore the antibody according to the present invention may have long circulating half-life in the body of the patient and it can be given at a reduced dosing frequency. The antibody according to the present invention can further be used in the preparation of a drug for treating diseases through inhibition of alternative complement pathway.

An external or topical formulation for treatment or prevention of infections involving body surfaces using a depsipeptide antibiotic drug such as lotilibcin having improved efficacy and safety is provided. The antibacterial effect of lotilibcin tested in infectious models is substantially enhanced by addition of boric acid in a low concentration of an additive level which does not produce any pharmacological activity by itself, thereby offering a formulation for external preparations having improved safety due to a decrease in dose, dosing period, and dosing frequency.

The invention provides a method of treating or controlling hypoparathyroidism in a human patient by administering to the human patient a pharmaceutical composition comprising a controlled-release PTH compound or a pharmaceutically acceptable salt thereof. The controlled-release PTH compound comprises a PTH moiety reversibly conjugated to a branched polyethylene glycol carrier. The composition is administered by subcutaneous injection no more frequently than once every 24 hours with a dosage of the controlled-release PTH compound that corresponds to no more than 70% of the molar equivalent dose of PTH 1-84 administered by subcutaneous injection at the same dosing frequency required to maintain a serum albumin-adjusted calcium level in serum of above 8.5 mg / dL over a 24 hour period.

The invention relates to an intelligent dosing method for advanced treatment of sulfate pulping wastewater. The intelligent dosing method comprises the steps of historical data collection, basic database establishment, intelligent dosing program modeling, program parameter optimization, real-time monitoring and feedback adjustment, dynamic adjustment and automatic control and the like. According to the method, historical data of the dosage of polymeric ferric sulfate under different COD values are collected, a dosage-COD value corresponding relation database is established, and a big data analysis technology is utilized for modeling. In actual operation, parameters, such as dosing frequency, temperature, flow and the like, of an intelligent dosing program are continuously optimized. The COD value of the treated wastewater is monitored in real time and compared with a theoretical value, the dosage is automatically adjusted according to a comparison result, and the wastewater treatment effect is ensured. When the actual COD value is higher than or lower than the theoretical value, the intelligent control system can automatically increase or decrease the dosage, so that the intelligence and automation of wastewater treatment are realized. According to the invention, the wastewater treatment efficiency and accuracy are improved, and the operation cost is reduced.

The disclosure provides improved human FGF23-binding antibodies with increased affinity for human FGF23 as compared to burosumab, enabling reduced dosing frequency, improving convenience of therapy, and achieving higher efficacy compared to burosumab, without compromising safety.

The present invention relates to therapeutic compositions and methods for the treatment of attention deficit disorder (ADD), or attention deficit hyperactivity disorder (ADHD). The present invention more particularly relates to a modified-release pharmaceutical formulation designed to improve the delivery and efficacy of central nervous system (CNS) stimulants. The composition consists of a drug-containing core with a CNS stimulant and pharmaceutically acceptable excipients. This core is coated with a sustained-release (SR) layer comprising one or more polymers selected from water-insoluble and water-insoluble pH-dependent polymers, and one or more pharmaceutically acceptable excipients which regulates the gradual release of the drug. Surrounding the SR layer is a delayed-release (DR) outer layer that controls the onset of drug release. This approach aims to enhance symptom control, reduce dosing frequency, and improve patient compliance in the treatment of ADD and ADHD.

This invention relates to wastewater treatment control technology, and discloses an intelligent carbon source dosing system and method for wastewater treatment with load sensing and allocation functions. The method includes: carbon source dosing, which involves adding carbon source to the anoxic tank and denitrification tank via a carbon source dosing pump unit; controlling the carbon source dosing frequency, which involves controlling the carbon source dosing frequency of the carbon source dosing pump unit via a carbon source dosing pump control cabinet; and feeding back the carbon source dosing amount to the carbon source dosing pump control cabinet; and determining the carbon source dosing amount, which is controlled by the intelligent carbon source dosing system through controlling the frequency of the carbon source dosing pump unit. The control of the carbon source dosing amount is achieved by controlling the carbon source dosing pump unit through the intelligent carbon source dosing system. This invention can detect the carbon source dosing amount in real time, and it offers good safety, low cost, and simple operation.

An autoserum eye drop administration device comprises a bottle body, a bottom cover and a bottle mouth, an arc-shaped tunnel is arranged in the bottle body, the upper end of the arc-shaped tunnel extends to the bottle mouth, the lower end of the arc-shaped tunnel extends to the bottom cover, a liquid medicine capsule is contained in the arc-shaped tunnel, a separation opening is formed in the side wall of the arc-shaped tunnel, one end of an elastic button is exposed out of the bottle body, and the other end of the elastic button extends to the separation opening. Extruding the liquid medicine capsule; the bottle neck is in threaded connection with the bottle body, a fine needle is arranged in the bottle neck, a fine needle reserved opening is formed in the upper portion of the arc-shaped tunnel, and the bottle neck is rotated to enable the fine needle to enter the arc-shaped tunnel from the fine needle reserved opening and pierce the liquid medicine capsule. By means of the structure, the autoserum eye drop dosing device can be matched with a liquid medicine capsule to conduct autoserum eye drop dosing, pollution is not prone to occurring, the dosing frequency can be increased, and waste is not prone to being caused.

The present invention relates to an injectable formulation, a method for treating a metabolic disease and an administration device. The injectable formulation comprises a lipid matrix composition, a specific amount of a GLP-1 receptor agonist and at least one pharmaceutically acceptable ion. Accordingly, upon contacting an aqueous fluid, the injectable formulation forms a depot exhibiting an extended release of the GLP-1 receptor agonist in vivo or in vitro. In the method for treating the metabolic disease, the injectable formulation can be administered to a subject with a reduced dosing frequency, and it is not necessary to store the injectable formulation for the next administration. For the administration device, the injectable formulation is filled in a vial, a pre-filled syringe or a pre-filled cartridge. Therefore, the injectable formulation can be designed for a single use, thereby enhancing convenience, compliance and adherence of a subject.

The utility model belongs to the technical field of sewage treatment, and particularly relates to a dosing device for rural sewage treatment, which comprises a barrel, a top cover is screwed at the top end of the barrel in a threaded manner, a water inlet pipe is fixedly mounted on the top cover, a bottom cover is screwed at the bottom of the barrel in a threaded manner, and a bent pipe is fixedly communicated with the barrel. A bent pipe is fixedly communicated with a through pipe, a height adjusting pipe is arranged at the top of the through pipe in a sliding and penetrating mode, a water outlet pipe is installed on the height adjusting pipe, and a locking assembly is installed between the through pipe and the height adjusting pipe. And the manual dosing frequency of personnel is effectively reduced.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a sustained-release analgesic pharmaceutical composition as well as a preparation method and application thereof. The pharmaceutical composition comprises a drug, a delivery carrier and a release regulator, the medicine is selected from at least one of local anesthetics and non-steroidal anti-inflammatory drugs; the release regulator is selected from phospholipid compounds; the delivery carrier is selected from saccharides and esters thereof. According to the invention, the phospholipid compound is adopted as the release regulator, and the phospholipid compound and the delivery carrier act together to increase the initial release blood concentration of the drug in vivo, shorten the peak time of the blood concentration, enhance the analgesic drug effect at the initial stage of the operation, maintain the long-acting release of the drug, effectively relieve the postoperative pain, reduce the administration frequency, and meanwhile, improve the bioavailability of the drug. The effects of promoting skin wound healing and repairing are also achieved; a specific type of solubilizer is adopted, so that the medicine has good stability and is not easy to separate out; in addition, the pharmaceutical composition disclosed by the invention can be directly administrated through a wound and is convenient to use.

The application discloses a kind of cannabidiol heat-sensitive nano hydrogel preparation and its injection and its preparation method, the injection includes cannabidiol 5-15mg / mL, Poly (I:C) 0.5-1.5mg / mL and Pluronic F127 concentration is 20-30wt%.The injection can slow-release cannabidiol and Poly (I:C) and prolong its residence time at tumor site, reduce dosing frequency, effectively and continuously synergistic inhibition tumor, reduce side effects.

The present invention relates to the technical field of pharmaceutical preparation, and specifically discloses a brivaracetam sustained-release dry suspension and a preparation method thereof. The brivaracetam sustained-release dry suspension of the present invention is composed of a sustained-release drug-loaded resin, a suspending agent and a flavoring agent. The brivaracetam dry suspension prepared by the present invention through ion exchange resin drug loading and then sustained-release coating has a sustained-release effect, can reduce the daily dosing frequency, and can also overcome the problems of difficult administration of tablets, inconvenient carrying of oral solutions, and troublesome administration methods of injections.

The present invention relates to the field of peptide drugs, and particularly to a triple-target peptide and a derivative thereof. The triple-target peptide provided by the present invention exerts effects of lowering blood glucose, reducing blood lipids, and weight loss. Based on the above studies, the triple-target peptide provided by the present invention is further long-acting modified, and while retaining excellent effects for the specific indications described above, also has long-acting advantages, which can reduce dosing frequency, improve medication convenience, and enhance patient compliance. Experimental results show that the peptide and the long-acting derivative thereof provided by the present invention can significantly lower blood glucose, reduce blood lipids and / or induce weight loss, and can effectively prevent, treat, or ameliorate diabetes, obesity, obesity-related diseases, or metabolic disorders.

Provided is a transdermal drug delivery system comprising dronabinol. The dronabinol transdermal delivery system provides a drug plasma concentration at predetermined rate for a predetermined period of time, offering a simplified therapeutic regimen by decreasing dosing frequency for the treatment and / or prevention of nausea and / or vomiting associated with, for example, chemotherapy.

Provided is a transdermal drug delivery system comprising tetrahydrocannabinol (THC). Transdermal delivery can provide a drug plasma concentration at predetermined rate for a predetermined period of time with a simplified therapeutic regimen by decreasing dosing frequency for the treatment and / or prevention of pain and / or inflammation.

Provided is a transdermal drug delivery system comprising tetrahydrocannabinol (THC). Transdermal delivery can provide a drug plasma concentration at predetermined rate for a predetermined period of time with a simplified therapeutic regimen by decreasing dosing frequency for the treatment and / or prevention of pain and / or inflammation.

To provide a treatment option that provides an extended duration of therapeutic action while reducing dosing frequency in the treatment of diabetes.SOLUTION: Provided are compounds comprising a therapeutic polypeptide Fc conjugate having activity at one or more of the GIP, GLP-1, and glucagon receptors. These compounds provide activity at one or more of these receptors and have structural features that extend the duration of action. Also provided are methods for treating diseases and / or conditions such as obesity, chronic weight management, and type 2 diabetes.SELECTED DRAWING: None

The present invention relates to the field of therapy. More particularly, the present invention relates to therapeutic methods in which effector components are administered that require cellular uptake to become effective and / or exert their effect via intracellular (molecular) targets, such as but not limited to nucleic acid or oligonucleotide therapeutic agents. The present invention provides modes that extend the duration of the effect of the effector component and / or extend the interval of administration of the effector component and / or reduce the frequency of administration of the effector component and / or cause a (delayed) enhancement of the effect of the effector component.

The present application relates to tap water data processing technical field, disclose two stage gradual tap water dosing quantity optimization method based on deep learning, including steps: input sequence data of current time into model M1, output predicted dosing frequency of distribution pool of current time, and turbidity at the end of filter pool of next time; adjust the predicted dosing frequency of distribution pool of current time, obtain the actual dosing frequency of distribution pool of current time;Optimization model M2 is trained using database;After training, input sequence data of current time, artificially set distribution pool dosing frequency selection sequence into optimization model M2, output predicted turbidity at the end of filter pool of next time;With optimal turbidity at the end of filter pool as target, adjust the actual dosing frequency of distribution pool of current time.The present application solves the data set and hysteresis problem existing when implementing intelligent control, and can realize the optimization control of flocculation reagent dosing through successive adjustment on the basis of risk control.

Provided is a transdermal drug delivery system comprising dronabinol. The dronabinol transdermal delivery system provides a drug plasma concentration at predetermined rate for a predetermined period of time, offering a simplified therapeutic regimen by decreasing dosing frequency for the treatment and / or prevention of nausea and / or vomiting associated with, for example, chemotherapy.

A single dosage form that delivers a tripulse (i.e., three pulses) release profile is provided. The dosage form includes at least three dosage units inside the final dosage form. By providing a single dosage form with multiple dosage units, the dosing frequency is decreased since precise blood levels of the active over a prolonged time period are controlled and achieved.